- Home
- TSLX vs RCKT Comparison
TSLX vs RCKT Comparison
Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- RCKT
- Stock Information
- Founded
- TSLX 2010
- RCKT 1999
- Country
- TSLX United States
- RCKT United States
- Employees
- TSLX N/A
- RCKT N/A
- Industry
- TSLX Investment Managers
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TSLX Finance
- RCKT Health Care
- Exchange
- TSLX Nasdaq
- RCKT Nasdaq
- Market Cap
- TSLX 1.9B
- RCKT 1.9B
- IPO Year
- TSLX 2014
- RCKT N/A
- Fundamental
- Price
- TSLX $20.40
- RCKT $17.13
- Analyst Decision
- TSLX Buy
- RCKT Strong Buy
- Analyst Count
- TSLX 7
- RCKT 9
- Target Price
- TSLX $22.43
- RCKT $53.22
- AVG Volume (30 Days)
- TSLX 231.8K
- RCKT 731.3K
- Earning Date
- TSLX 11-05-2024
- RCKT 11-04-2024
- Dividend Yield
- TSLX 11.58%
- RCKT N/A
- EPS Growth
- TSLX 4.41
- RCKT N/A
- EPS
- TSLX 2.36
- RCKT N/A
- Revenue
- TSLX $473,575,000.00
- RCKT N/A
- Revenue This Year
- TSLX $10.80
- RCKT N/A
- Revenue Next Year
- TSLX N/A
- RCKT $300.20
- P/E Ratio
- TSLX $8.64
- RCKT N/A
- Revenue Growth
- TSLX 23.94
- RCKT N/A
- 52 Week Low
- TSLX $19.33
- RCKT $15.98
- 52 Week High
- TSLX $22.35
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- TSLX 45.10
- RCKT 46.41
- Support Level
- TSLX $20.33
- RCKT $17.05
- Resistance Level
- TSLX $20.81
- RCKT $17.75
- Average True Range (ATR)
- TSLX 0.20
- RCKT 0.72
- MACD
- TSLX -0.01
- RCKT 0.06
- Stochastic Oscillator
- TSLX 23.81
- RCKT 40.23
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.